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Abstract 
The frequency and range of long-term
sequelae following acute Q fever infection
remains controversial. This study aimed to
assess a range of potential psychological and
physical sequelae in a follow up study of a large
outbreak of Q fever that occurred in Newport,
Wales, in 2002. A nested case control study was
undertaken six years after a point source out-
break of Q fever. We invited a cohort of 211 fac-
tory workers exposed to a point source of Q
fever in 2002 to attend a follow up clinic in
2008. Cases, defined as those who had clinical
symptoms and serological evidence of acute Q
fever in 2002, were compared to controls, who
worked in the same factory but were serologi-
cally negative at the time of the outbreak. At
the follow up clinic blood was taken for
Coxiella burnetii microimmunofluorescence
and questionnaires were completed including
the PHQ-9, Chalder Fatigue scale, and General
Health Questionnaire. Results were obtained
for 32 cases and 13 controls. Chalder Fatigue
scores were significantly raised in the cases
(independent samples t-test: P=0.047). PHQ-9
and GHQ scores were not significantly raised
in cases. However, post hoc cross sectional
analysis indicated a relationship between
Phase 2 IgG at follow up in 2008 and Chalder
Fatigue scores (P=0.004) and PHQ-9 scores
(0.049). A longitudinal association was
demonstrated between acute Q fever infection
and chronic fatigue six years later. In cross-
sectional analysis a previously unreported
relationship between depression scores (PHQ-
9) and positive Q fever serology was also iden-
tified.
Introduction
A number of follow up studies of patients
with acute Q fever1-8 and serological examina-
tion of patients presenting with Chronic
Fatigue Syndrome,9 have indicated that Q fever
may be associated with chronic fatigue. A rela-
tionship between previous Q fever and symp-
toms of depression can also be postulated.10
The underlying aetiology of the association
between Q fever and chronic fatigue remains
unclear. The extent to which chronic symptoms
are influenced by the strain of C. burnetii, psy-
chosocial factors, immunological or genetic
factors is also uncertain.11,12 The possibility of
long term effects following acute infection is
supported by evidence that the aetiological
organism can be detected in a proportion of
patients by PCR many years later.13-15 It is still
unclear whether patients that have long stand-
ing chronic fatigue after acute Q fever gain
any benefit from antibiotic treatment.16,17
A point source outbreak of Q fever occurred
in a cardboard manufacturing plant in
Newport, South Wales, in 2002.18 This out-
break was one of the largest to have occurred
in the UK. During the initial outbreak, the
exposed cohort was identified and a nested
case control study was undertaken to assess
the difference in exposure between cases and
controls to a range of potential sources of the
outbreak. The cohort of factory workers,
including affected and unaffected individuals
provided the opportunity for a follow up study,
which was conducted six years later in 2008.
The serological findings of the follow up study
have been published.19 The current paper com-
pares the symptoms of the original cases and
controls in a follow up study. The aim of the
study was to assess the hypotheses that i)
chronic fatigue, ii) depression and iii) reduced
physical function were more common in those
who had acute Q fever in 2002 compared to
those individuals in the cohort who worked in
the same factory but did not demonstrate evi-
dence of infection at the time of the outbreak.
Materials and Methods
From the initial cohort of 226 individuals
who worked in the factory in 2002, all 131 sero-
logically positive cases were invited to take
part in the follow up study in 2008, as were a
random sample of 80 of the 95 serologically
negative individuals. A written invitation to
participate, including a leaflet outlining the
proposed study, was therefore sent to 211
potential participants.
Those individuals who agreed to take part in
the study were invited to a clinic where blood
was taken for microimmunofluorescence test-
ing for presence of Coxiella burnetii Phase 2
IgG and IgM antibodies and Phase 1 IgG and
IgA antibodies. The microimmunofluorescence
assays used antigen from Patient strain Lane -
ST12 group. The blood samples were analysed
by the standard reference laboratory in the UK,
the Special Pathogens Reference Unit, HPA
Centre for Emergency Preparedness and
Response, Porton Down, Salisbury, SP4 0JG.
Questionnaires including the PHQ-920 which
assesses the severity of symptoms of depres-
sion, the 11 item version of the Chalder
Fatigue scale,21 and the General Health
Questionnaire (GHQ) which assesses physical
health22 were completed at the clinic. The
questionnaire included two new single item
tests for fatigue. Firstly, If you are tired at the
moment how long has this lasted? Response
options were not reported being tired, less than
one week, one week to 3 months, 3 to 6 months,
6 months or more. For analysis the results were
dichotomised into those who had fatigue for
six months or more and those who had fatigue
for less than six months. Secondly, the ques-
tionnaire asked, What percent of the time do
you feel tired? Response options were 0%, 25%,
50%, 75%, or 100% of the time. Responses
were dichotomised into those who reported
being tired less than 50% of the time and 50%
of the time or more.
The PHQ-9 is a self-administered subset of
the PRIME-MD diagnostic instrument for com-
mon mental disorders. It is a widely used and
well validated measure of depression based on
nine questions that start with the stem, Over
the last 2 weeks, how often have you been both-
ered by any of the following problems? Answers
range from 0 (not at all) to 3 (nearly every
day). The Chalder Fatigue scale used in this
analysis contains 11 questions covering the
physical and mental symptoms of fatigue
including, tiredness, need to rest, feeling
drowsy, problems starting things, and difficulty
concentrating. The General Health Question-
naire is a broad ranging and widely used meas-
ure of physical health. The two other questions
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on fatigue duration and percent of time affect-
ed by fatigue were not previously validated
questions.
Questionnaire data was analysed using
Microsoft Excel® and SPSS®. In view of the rel-
atively small sample sizes, the non-parametric
Mann-Whitney U test for two independent
samples was used to compare variables.
Variables were also dichotomised and com-
pared using the chi-square test. Fishers’ exact
test was used where where one cell had an
expected count of less than five.
Ethical approval for the study was granted by
the South East Wales Research Ethics
Committee Panel C.Longitudinal and cross sectionalanalyses
The data was analysed as a nested case con-
trol study, based on the status of participants
in 2002 as cases or controls. In 2002 cases
were defined as those members of the exposed
cohort who had clinical symptoms of acute Q
fever infection and serological evidence of
infection as demonstrated by a Phase 2 IgM
≥80, or a fourfold rise on sequential Comple-
ment Fixation Tests (CFT). Non-cases were
defined as those who had no symptoms of
acute Q fever infection and no serological evi-
dence of infection with no IgM, no CFT and no
Phase 1 or 2 IgG. Three patients who did not
unambiguously meet criteria as cases or con-
trols were excluded from analysis. They had
uncertain serology defined as no IgM, no four-
fold rise in CFT but CFT ≥ 8 or Phase 1 or 2 IgG
> 160. Two of the three individuals with uncer-
tain serology had symptoms; the third individ-
ual did not. These three individuals were
excluded from all the analysis presented in this
paper.
A post hoc cross sectional analysis of the
cohort was also undertaken, assessing the
relationship between current clinical symp-
toms at the time of the clinic in 2008 and
Phase 2 IgG blood results from samples taken
at the same time. Phase 2 IgG titres were
recorded as 0, 320, 640, 1280, or 2560. Scores
for clinical symptoms were dichotomised as
follows: Chalder Fatigue (0-3, 4-11); PHQ-9
scores (dichotomised at the median: 0-3, 4-9);
duration of tiredness (less than 6 months, 6
months or more); percent of time participants
felt tired (less than 50% of the time, 50% of the
time of more); and GHQ scores (dichotomised
at the median: 0-2, 3-12).
Results
Results for analysis were available for 45
individuals out of a total of 52 individuals who
attended the follow up clinic. This represented
24.4% of cases invited to the clinic (32/131)
and 16.3% of the controls invited to the follow
up clinic (13/80). The characteristics of the
cohort used for the nested case control study
are shown in Table 1. Both groups were pre-
dominantly male, reflecting the population in
the factory where the outbreak occurred. The
mean age of cases was 50.18 yrs (SD 9.85,
range 27-64 yrs) and the mean age of controls
was 53.57 yrs (SD 8.86, range 36-68 yrs).
Educational attainment was similar in both
groups: 37.5% (12/32) of cases and 38.5%
(5/13) of controls had remained in education
after the minimum school leaving age.
Nested case control study
A table showing the relationship between
status in 2002 and symptoms in 2008 is provid-
ed in Table 2. Raised Chalder Fatigue scores
were more common in cases (P=0.047). The
single questions analysing symptoms of tired-
ness for 6 months or more or tiredness for 50%
of the time or more were not statistically signif-
icantly associated with being a case. Neither
were PHQ-9 scores (P=0.189) or GHQ scores
(P=0.743).Cross sectional analysis
A second post hoc analysis of the cohort was
Article
Table 1. Summary of cases and controls (bases on status in 2002) by gender.
Status Total
Case Control
Gender
Female 7 1 8
Male 28 13 44
Total 35 14 52
Table 2. Relationship between status as defined in 2002 (cases and controls) and clinical
symptoms in 2008.
Comparison N Cases Controls Fisher’s
Exact
test P
Chalder fatigue score 0-3 4-11 0-3 4-11
45 13 19 10 3 0.047
Tired for 6 months or more < 6 months ≥ 6 months < 6 months ≥ 6 months
39 11 17 8 3 0.082
Tired for 50% of the time or more 0-50% 50-100% 0-50% 50-100%
40 7 21 6 6 0.154
PHQ-9 1-3 4-9 1-3 4-9
45 14 18 9 4 0.189
GHQ 0-2 3-12 0-2 3-12
49 22 13 10 4 0.743
Table 3. Relationship between Phase 2 IgG in 2008 and symptoms measured at the same
time.
Comparison N Mean  rank Sum of Mann-
Ranks whitney U
Phase 2 IgG Chalder Fatigue score (0-3) 23 17.91 412.00 136.000
Chalder Fatigue score (4-11) 22 28.32 623.00 P = 0.004
Total 45
Phase 2 IgG Tired for 6 months or more 19 16.45 312.50 122.500
Not tired for 6 months or more 20 23.38 467.50 P = 0.037
Total 39
Phase 2 IgG Tired less than 50% of the time 13 14.69 191.00 100.000
Tired 50% of the time or more 27 23.30 629.00 P = 0.017
Total 40
Phase 2 IgG PHQ-9 score (0-3) 23 19.52 449.00 173.000
PHP-9 score (4 – 9) 22 26.64 586.00 P = 0.049
Total 45
Phase 2 IgG GHQ score (0-2) 32 23.86 763.50 235.500
GHQ score (3-12) 17 27.15 461.50 P = 0.406
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undertaken to assess whether symptoms
recorded at the follow up clinic in 2008 were
associated with Phase 2 IgG results taken at
the same time (Table 3). There was a clear
relationship between higher C. burnetii Phase
2 IgG and raised Chalder Fatigue score (P=
0.004), tiredness for 6 months or more (P=
0.037), tiredness for 50% of the time or more
(P=0.012), and raised PHQ-9 score (0.049),
but not GHQ score (P=0.406).
Similarly, dichotomising C. burnetii Phase 2
IgG scores to 0-640 and 1280-2560 and assess-
ing the relationship with symptoms using the
chi-square test indicated a clear relationship
to clinical symptoms of fatigue: Chalder
Fatigue score (chi-square 8.049; P=0.005),
tiredness for 6 months or more (chi-square
4.311; P=0.038), tiredness for 50% of the time
or more (chi-square 6.686; P=0.01).
Relationships with PHQ-9 score (chi-square
2.702; P=0.1), and GHQ score (chi-square
0.634; P=0.426) were not statistically signifi-
cant. Four of the fourteen control subjects
(based on their status in 2002) had C. burnetii
Phase 2 IgG titres of 320 for Q fever at follow
up in 2008.
Discussion
Chalder Fatigue scores were significantly
raised six years later in those individuals who
were diagnosed with acute Q fever at the time
of the outbreak. In contrast, general health, as
measured by the GHQ, was not significantly
different from controls drawn from the same
cohort of individuals who worked in the same
factory at the time of the outbreak. There is a
statistically significant cross-sectional rela-
tionship (P=0.049) at the time of follow up
between raised serology by microimmunofluo-
rescence and both Chalder Fatigue scores and
depression as measured by the PHQ-9.
Symptoms of fatigue and depression can over-
lap and can be difficult to differentiate.
However, as these results were derived from
the cohort of workers exposed to Q fever in the
initial outbreak in 2002, there is some evi-
dence to suggest that depression may be a
associated with previous Q fever infection.
This finding will need verified by future stud-
ies. An unexpectedly large proportion of the
controls (28.6%) were serologically positive at
follow up. This figure is much higher than the
sero-prevalence of Q fever in the UK popula-
tion.23 The positive Q fever serology may repre-
sent late sero-conversion due to exposure at
the time of the outbreak, later exposure to Q
fever, or false positive results. 
The main strength of this study was that it
used validated questionnaires to assess symp-
toms associated with the long term sequelae of
Q fever subsequent to a point source outbreak.
The study was also strengthened by the fact
that controls were drawn from the same envi-
ronment as cases. However, some controls may
indeed have been unidentified asymptomatic
cases and a separate population of control sub-
jects would have strengthened this study fur-
ther. The potential inclusion of some cases in
the control group would reduce the power of
the study to detect an effect and should, there-
fore, not have introduced bias in favour of our
findings.
The sample size in this study is small and
the response rate is relatively low. Participants
were aware whether or not they had been diag-
nosed as having acute Q fever in initial out-
break and this may have introduced some
reporting bias when completing the follow up
questionnaires. Potential problems in inter-
preting serological results and defining inter-
national standards for acute, past and chronic
infection have been considered in a previous
report.19
It would have been helpful to have informa-
tion on other blood borne infections that could
have contributed to chronic fatigue. However,
we have no reason to suspect that the preva-
lence of such infections would be different in
cases and controls. Consequently, this issue
should not have materially affected our find-
ings. It would have been interesting to assess
whether there was a relationship between the
nature of the work undertaken by each partici-
pant in the study and their level of fatigue. In
particular, whether there was a relationship
between the symptoms of chronic fatigue and
the level of physical exertion undertaken on a
day to day basis or the shift pattern worked by
the individuals concerned. It would also have
been useful to compare the frequency and
duration of sick leave in cases and controls.
Unfortunately, none of this information was
collected. One patient from this cohort devel-
oped Q fever endocarditis and was treated with
antibiotics. However, it is unclear whether or
not chronic fatigue after Q fever infection
should be treated with antibiotics. Raised Q
fever serology is more common in patients
with Chronic Fatigue Syndrome than in the
background population.9 Small studies have
shown that some patients with chronic fatigue
and raised Q fever serology respond to antibi-
otic treatment.16,24 However, high antibody lev-
els may indicate high responder status rather
than the actual presence of the microorgan-
ism. This study points up the desirability of a
trial of antibiotics in patients with post q fever
chronic fatigue.
Conclusions
This study has demonstrated that chronic
fatigue was more common six years later in
patients who were infected with Q fever during
an outbreak. The study has also raised the pos-
sibility of a relationship between raised C. bur-
netii Phase 2 IgG and symptoms of chronic
fatigue and depression. 
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